Cencora assumes no obligation to update any ... in specialty in a high growth pharmaceutical-centric segment, building on our services for our customers and positioning us well in a medical ...

Cencora assumes no obligation to update any ... leadership in specialty in a high-growth pharmaceutical-centric segment building on our services for our customers and positioning us well in ...

Over the past year, many Cencora, Inc. ( NYSE:COR ) insiders sold a significant stake in the company which may have... CONSHOHOCKEN, Pa., February 07, 2025--Cencora, Inc. (NYSE: COR) today ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D ...

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal first-quarter net income of $488.6 million. The Conshohocken, Pennsylvania-based company said ...

Cencora assumes no obligation to update any forward-looking statements ... fits squarely into our strategy and growth by expanding our leadership in specialty in a high-growth pharmaceutical-centric ...